Beranda › Dermatomiositis › Maryland › Baltimore
Uji klinis Dermatomiositis di Baltimore, MD
4 studi untuk Dermatomiositis mencari peserta di lokasi sekitar Baltimore (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Menerima pesertaFase 3
- Research Site, Baltimore
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Menerima pesertaFase 1
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Menerima pesertaFase 1
- Johns Hopkins Hospital, Baltimore
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Menerima pesertaFase 1
- Johns Hopkins University, Baltimore
Uji klinis Dermatomiositis di kota lain
- Durham, NC8 studi
- Washington, DC7 studi
- New York City, NY5 studi
- Pittsburgh, PA5 studi
- Boston, MA5 studi
- Houston, TX5 studi
- Philadelphia, PA4 studi
- Miami, FL4 studi
- Cleveland, OH3 studi
- Jacksonville, FL3 studi
- Aurora, CO3 studi
- Kansas City, KS3 studi
Studi lain di Baltimore
- Kanker Paru Non-Sel Kecil60 studi
- Kanker Payudara47 studi
- Kanker Prostat43 studi
- Kanker Paru40 studi
- Kanker (semua jenis)37 studi
- Kanker Kolorektal31 studi
- Kanker Pankreas31 studi
- Kanker Metastatik28 studi
- Obesitas25 studi
- Gagal Jantung24 studi
- Kanker Kandung Kemih24 studi
- Stroke22 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.